Black Cohosh

Actaea racemosa

Family: Ranunculaceae Part used: Root and rhizome

Key Compounds

• Actein
• Cimicifugoside
• 27-Deoxyactein
• Acerinol
• Cimiracemoside A
• Fukinolic acid
• Cimicifugic acids
• Isoferulic acid
• Formononetin
• Caffeic acid
• Salicylic acid
• Tannins

Traditional Use

• Menopausal symptom reduction — multiple clinical trials and meta-analyses showing reduction in hot flash frequency and severity; the Cimicifuga racemosa extract Remifemin was approved by German Commission E in 1989; a 2010 Cochrane-style meta-analysis of 16 RCTs found consistent evidence of hot flash reduction
• Serotonergic rather than oestrogenic mechanism — black cohosh was classified as phytoestrogenic for decades; this classification drove safety concerns about hormone-sensitive conditions; 2003 research demonstrated that black cohosh does NOT bind to oestrogen receptors; subsequent research identified serotonergic binding (5-HT7 receptor agonism) as the probable mechanism for hot flash reduction; this mechanism revision changes the risk profile significantly
• Cherokee traditional medicine — Algonquian peoples used the root for 'female complaints' and rheumatic conditions; Cherokee used *Actaea racemosa* for menstrual regulation and as a parturient; the plant's introduction to European-American medicine in the 19th century came directly from indigenous use
• Premenstrual and perimenopausal use — traditional and clinical use for menstrual cramping, breast tenderness, and mood disruption associated with hormonal transitions; the serotonergic mechanism may explain mood-related effects alongside hot flash reduction
• Remifemin extract — the standardised German pharmaceutical extract used in most clinical trials; 20-40 mg twice daily; standardised to triterpene glycoside content; the clinical evidence base is for this specific extract, not generic black cohosh preparations
• Sleep support in menopause — several clinical trials show improvement in sleep quality alongside hot flash reduction; serotonin involvement in sleep regulation may account for this secondary benefit

The medicine was approved in Germany in 1989. The mechanism was not understood until 2003.

The German Commission E approved black cohosh root extract (Remifemin) for menopausal and premenstrual symptoms based on the clinical trial evidence. The approval was made, appropriately, on the basis of what the plant did — reduced hot flashes — rather than on a complete understanding of how it did it. The mechanism was assumed, incorrectly, to be phytoestrogenic.

When better research arrived in the early 2000s, it turned out that black cohosh does not bind to oestrogen receptors. The mechanism is serotonergic. The approval was correct. The explanation had been wrong.

Meet the plant

A tall, graceful perennial herb of North American eastern forests. 1.5–2.5 metres when flowering, with long wand-like racemes of small white flowers. The roots and rhizome are black — the source of the common name. The Algonquian word cohosh means rough or knobbly, describing the rhizome texture.

The flowers smell disagreeable enough to attract flies. This is by design.

The mechanism question

For approximately twenty years, black cohosh was classified as phytoestrogenic — assumed to work by mimicking oestrogen. Hot flashes are caused by oestrogen decline; the herb reduced hot flashes; therefore the mechanism must involve oestrogen. This logic was wrong.

In 2003, Jarry et al. demonstrated that black cohosh does not bind to oestrogen receptors. Subsequent research identified serotonin receptor agonism (specifically 5-HT7 receptors) as the probable active mechanism. This matters because serotonin dysregulation is independently involved in hot flash physiology — vasomotor symptoms in menopause are not purely caused by oestrogen decline but involve serotonin and norepinephrine pathways as well. The serotonergic mechanism explains the efficacy without requiring oestrogenic activity.

This distinction is not academic. The previous classification as phytoestrogenic created safety concerns for women with oestrogen-sensitive cancers — breast cancer survivors, in particular. The revised mechanism changes the theoretical risk profile. The practical clinical guidance has moved from ‘contraindicated in hormone-sensitive conditions’ to ‘use with caution and discuss with your oncologist.’

The evidence

Clinical trial evidence for menopausal hot flash reduction is consistent across multiple trials. The German pharmaceutical preparation Remifemin (standardised extract, 20–40 mg twice daily) was used in most of the well-designed trials. A meta-analysis of 16 RCTs found consistent evidence of hot flash frequency and severity reduction versus placebo.

Effect size: approximately 25–30% reduction in hot flash frequency compared to placebo. This is meaningful for mild to moderate symptoms. It is less than hormone replacement therapy, which is more effective for severe symptoms.

The clinical trial evidence is for the standardised extract, not generic preparations. This distinction matters — black cohosh content and extract quality vary considerably between products.

The Cherokee origin

Black cohosh was used by Cherokee, Algonquian, and other eastern North American peoples for women’s health conditions — menstrual irregularity, difficult childbirth, and ‘female weakness’ — before European contact. The name cohosh is Algonquian.

European-American physicians encountered it in the 19th century through contact with indigenous herbalists. It appeared in the US Pharmacopoeia from 1820 to 1926. German pharmaceutical companies developed standardised extracts in the 20th century based on the documented traditional use. The Remifemin approval in 1989 completed the route from indigenous knowledge to pharmaceutical product.

The chemistry

Triterpene glycosides (actein, cimicifugoside, 27-deoxyactein): the primary pharmacological compounds; the serotonergic activity was identified primarily in these compounds.

Cimicifugic and fukinolic acids: contribute to the overall activity profile.

Isoferulic acid: anti-inflammatory.

What people actually do with it

Standardised extract (primary clinical use): Remifemin or equivalent, 20–40 mg twice daily. Most clinical trial evidence is for this specific preparation. Allow 4–8 weeks for effect.

General recommendation: 6 months maximum continuous use without a break. This is a precautionary guideline given the unresolved liver toxicity signal.

Tincture: 1–2 mL twice daily of root tincture. Less standardised than pharmaceutical preparations.

Combination products: Black cohosh is commonly combined with other herbs (St. John’s Wort, dong quai, sage) in menopausal support formulations. Clinical evidence is for single-herb preparations.

Could you grow this yourself?

In eastern North America or temperate woodland gardens: yes, though it is a slow-growing shade-tolerant plant. Full shade to partial shade, moist humus-rich soil. The flowering stalks are architecturally dramatic in summer.

Commercial wild harvesting has created conservation concerns. Cultivated sources are preferable for ethical and sustainability reasons.

Black Cohosh (ブラックコホシュ) in Japan

Actaea species native to Japan are used in kampo as 升麻 (shōma) — different species from A. racemosa, used for infections, headaches, and fevers in classical Chinese medicine applications. The Japanese kampo use is separate from the Western menopausal application.

Western black cohosh supplements (ブラックコホシュ) are available in Japan positioned for menopausal support. Japanese women approaching menopause encounter it as one option among adaptogenic and hormone-balancing supplements. The Remifemin extract is distributed in Japan.

Things you’re probably wondering

Is it oestrogenic? No — research in 2003 established it does not bind oestrogen receptors. The mechanism is serotonergic (5-HT7 receptor agonism). The previous phytoestrogenic classification was wrong.

What is Remifemin? The standardised German pharmaceutical extract, 20–40 mg twice daily, approved by German Commission E in 1989. Most clinical evidence is for this preparation.

Is there a liver risk? Approximately 40–70 case reports of liver injury are in the literature; causality is not clearly established. Standard guidance: limit to 6 months continuous use; stop if jaundice or dark urine appears.

Is it safe for breast cancer survivors? The mechanism revision reduces the theoretical concern. Current guidance is ‘use with caution; discuss with oncologist’ rather than ‘contraindicated.’

Botanical details

The full compound list

See Also

• Ashwagandha — adaptogen with evidence for perimenopausal stress; different mechanism
• Valerian — sleep support in menopause; serotonergic mechanisms overlap
• Red Clover — genuinely phytoestrogenic isoflavone herb; comparison is instructive

References

• Jarry, H. et al. (2003). Evidence for estrogen receptor β-selective activity of Cimicifuga racemosa. Planta Medica, 69(10), 945–947.
• Borrelli, F. & Ernst, E. (2008). Black cohosh for menopausal symptoms. Pharmacological Research, 58(1), 8–14.
• Ross, S.M. (2012). Menopause: A standardized extract of black cohosh (Remifemin). Holistic Nursing Practice, 26(1), 58–61.
• NCCIH. (2020). Black Cohosh. National Institutes of Health.